Immunotherapy for metastatic renal cell cancer: effect on the primary tumor.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Immunotherapy for metastatic renal cell cancer: effect on the primary tumor.

J Immunother. 1993 Feb;13(2):130-5. Unique Identifier : AIDSLINE MED/93305660
Haas GP; Redman BG; Rao VK; Dybal E; Pontes JE; Hillman GG; Department of Urology, Wayne State University School of Medicine,; Harper Hospital, Detroit, Michigan.

Abstract: The traditional approach to immunotherapy for metastatic renal cell cancer, to first reduce the tumor burden by nephrectomy and then offer systemic therapy, has been challenged recently. There is mounting evidence that objective responses in the metastatic disease can be achieved without prior nephrectomy, although responses in the primary tumor are much less frequent. We describe our experience that some patients may, in fact, have significant responses in extensive local disease and become surgical candidates after systemic immunotherapy. A 46-year-old patient who presented with a large renal primary tumor and pulmonary metastases was treated with high-dose interleukin 2 therapy. A complete response in the lung and partial response in the primary tumor was achieved. The patient then underwent resection of his primary tumor, and on histological evaluation only minimal residual cancer was present. He has no evidence of disease at 14 months. This case demonstrates that immunotherapy can achieve not only objective responses at metastatic sites but also in the primary tumor.

Keywords: Carcinoma, Renal Cell/IMMUNOLOGY/*SECONDARY/*THERAPY Case Report CD4-CD8 Ratio Human *Immunotherapy Interleukin-2/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Kidney Neoplasms/IMMUNOLOGY/*THERAPY Lung Neoplasms/IMMUNOLOGY/*SECONDARY/*THERAPY Male Middle Age Nephrectomy Support, Non-U.S. Gov't JOURNAL ARTICLE
931030
M93A0719

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .